This HTML5 document contains 159 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1097/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34026037
rdf:type
wikibase:Item
schema:description
2010年論文 мақолаи илмӣ scienca artikolo teaduslik artikkel мақолаи илмӣ artigo científico (publicado na 2010) 2010年论文 2010年の論文 mokslinis straipsnis наукова стаття, опублікована в серпні 2010 บทความทางวิทยาศาสตร์ wetenschappelijk artikel مقالة علمية bilimsel makale 2010年論文 2010年论文 научная статья articol științific artículo científico publicado en 2010 2010 թվականի օգոստոսին հրատարակված գիտական հոդված vetenskaplig artikel artikulong pang-agham article scientifique (publié 2010) 2010年論文 научни чланак 2010年論文 سائنسی مضمون ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artigo científico (publicado na 2010) vitenskapelig artikkel 2010년 논문 επιστημονικό άρθρο სამეცნიერო სტატია bài báo khoa học научни чланак מאמר מדעי 2010年论文 tudományos cikk 2010年論文 vedecký článok scientific article articolo scientifico artículu científicu espublizáu en 2010 vitskapeleg artikkel 2010 nî lūn-bûn 2010年论文 artigo científico artykuł naukowy videnskabelig artikel (udgivet 2010) vědecký článek tieteellinen artikkeli naučni članak научна статия 2010年论文 2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած مقالهٔ علمی wissenschaftlicher Artikel artikull shkencor 2010年论文 article scientific article científic
p:P577
wds:Q34026037-CFBC6126-2861-404E-91A9-80938E3AC37E
wdt:P577
2010-08-01T00:00:00Z
p:P407
wds:Q34026037-E92D05DF-DF73-4C90-899F-396B488052F8
wdt:P407
wd:Q1860
p:P2860
wds:Q34026037-3A4537D4-9954-45C8-8923-A659A5B46626 wds:Q34026037-45A61519-4C82-49DC-8CFA-C6378F2893CF wds:Q34026037-47937EE8-8F62-46F2-8527-9F0AAFB96C67 wds:Q34026037-7D6FEA06-4B17-43E0-B0D9-DC0D675143C6 wds:Q34026037-8060B033-E9FF-4B4A-A497-722620892A19 wds:Q34026037-876AC46A-FD8F-40A7-A230-64CA5D3DEC49 wds:Q34026037-8955A29A-CA36-49FF-81AE-81A8EAFC237B wds:Q34026037-89E8BE55-EE2C-4B09-8847-48488A5C6ABC wds:Q34026037-95C72BC2-BA8E-4D0C-8F74-CB2339CCFFE6 wds:Q34026037-9D0FF098-4938-4BF6-9D0C-D35A4CAD5692 wds:Q34026037-A30648E6-E976-41A3-A707-B6B3A49A882E wds:Q34026037-A9B59958-BC83-4739-9EB1-CD3C67523412 wds:Q34026037-AD948430-4C93-48DA-820C-50D17CEC6C94 wds:Q34026037-C0990170-1C00-48A1-A65E-EDED75DD7100 wds:Q34026037-D1167998-EB05-4662-9CE3-AF265B6CAA67 wds:Q34026037-F08EF322-096F-4DC9-B056-53C7322BB709 wds:Q34026037-013A50F1-82BE-4183-9DDE-524753156469 wds:Q34026037-06BEA5EB-709B-44FE-88FE-4BE044407E75 wds:Q34026037-1569B93B-0799-44F7-90AB-4ABBC51B66CE wds:Q34026037-2BA6B46A-27A7-4273-959E-DA69268B4375 wds:Q34026037-FD549BCB-21C7-4D2A-B6E6-A8A102C331A2
wdt:P2860
wd:Q81317582 wd:Q44016800 wd:Q50789972 wd:Q43430750 wd:Q33373436 wd:Q33328193 wd:Q36644123 wd:Q37121685 wd:Q33383835 wd:Q74534930 wd:Q24658198 wd:Q34417759 wd:Q40838931 wd:Q79370331 wd:Q27860704 wd:Q28251373 wd:Q37121729 wd:Q40217269 wd:Q40990202 wd:Q37633813 wd:Q51656955
p:P2093
wds:Q34026037-259A6744-3C39-4C69-947F-F8EEC02D6F4E wds:Q34026037-01C98342-DE50-4248-9986-896B8028804C wds:Q34026037-BBF0BE7A-0A4F-4F39-8424-2938FB4A605D wds:Q34026037-9C9BCCAA-D939-485A-9F17-6589B15850C9 wds:Q34026037-DB01B507-C738-402A-BBED-934F01A299BC wds:Q34026037-51BF4B62-6AC4-4803-8287-0C525BDB760F
wdt:P2093
Chandra P Belani Philip C Mack Marianna Koczywas S Percy Ivy Ramaswamy Govindan Suresh S Ramalingam
rdfs:label
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
skos:prefLabel
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
schema:name
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
p:P50
wds:Q34026037-C8235FC6-149D-4ADB-9DAE-1D0318A978E1 wds:Q34026037-A03C85B5-03F4-4627-972B-F170A1F98E63 wds:Q34026037-56C2894D-6B16-4A78-BB58-7F0B76630932
wdt:P50
wd:Q73567428 wd:Q73567194 wd:Q30792585
p:P1476
wds:Q34026037-529E9A62-D759-4139-8A15-25AC02A0C8A3
wdt:P1476
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
p:P304
wds:Q34026037-FDA9CA9D-82CF-4460-BD3D-268878057B7B
wdt:P304
1279-1284
p:P31
wds:Q34026037-1C7388BB-CCE7-4C59-A0C9-209737955666
wdt:P31
wd:Q13442814
p:P921
wds:Q34026037-199A0B9A-6B74-445B-8457-B5D97FF4B7F1 wds:Q34026037-8E370C32-0F1C-43A7-8CEE-D56F76E78FD2
wdt:P921
wd:Q47912 wd:Q111140
p:P698
wds:Q34026037-9B289F1A-7F8A-4046-B779-18BB721A6D6C
wdtn:P698
n10:20559150
wdt:P698
20559150
p:P1433
wds:Q34026037-9034F2DA-D4D5-4B02-8E9E-959CEC9DBD53
wdt:P1433
wd:Q2448056
p:P433
wds:Q34026037-D591E75C-DB93-4424-B0CE-EC845A2493D4
p:P478
wds:Q34026037-41C0E68D-F0AE-43F0-9B8E-E090D9317221
wdt:P433
8
wdt:P478
5
p:P356
wds:Q34026037-D24B9ADE-9047-4AFB-AE2D-EF14F50904C8
wdtn:P356
n12:JTO.0B013E3181E2FCB0
wdt:P356
10.1097/JTO.0B013E3181E2FCB0
p:P932
wds:Q34026037-21CC515F-CE16-4A6F-95D0-F498C3B4EA8C
wdt:P932
2911495